Evidence map›Paper›PMID 39247345›Full record

ArticleHeliyon2024

A new route to the synthesis of 2-hydrazolyl-4-thiazolidinone hybrids, evaluation of α-glucosidase inhibitory activity and molecular modeling insights.

Saghi Sepehri, Ghazaleh Farhadi, Maryam Maghbul, Farough Nasiri, Mohammad Ali Faramarzi, Karim Mahnam, Somayeh Mojtabavi, Mohammad Mahdavi, Zhaleh Moharrami Oranj

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saghi SepehriPharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Ghazaleh FarhadiStudents Research Committee, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Maryam MaghbulDepartment of Applied Chemistry, University of Mohaghegh Ardabili, Ardabil, Iran.
Farough NasiriDepartment of Applied Chemistry, University of Mohaghegh Ardabili, Ardabil, Iran.
Mohammad Ali FaramarziDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Karim MahnamDepartment of Biology, Faculty of Sciences, Shahrekord University, Shahrekord, Iran.
Somayeh MojtabaviDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zhaleh Moharrami OranjDepartment of Applied Chemistry, University of Mohaghegh Ardabili, Ardabil, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the multifactorial worldwide health syndromes is diabetes mellitus which is increasing at a disturbing rate. The inhibition of α-glucosidase, an enzyme that catalyzes starch hydrolysis in the intestine, is one helpful therapeutic approach for controlling hyperglycemia related to type-2 diabetes. To discover α-glucosidase inhibitors, some 2-hydrazolyl-4-thiazolidinone hybrids (

Indexed as

DiabetesDocking studyIn silico studyMolecular dynamics simulationsα-glucosidase

Identifiers

PMID39247345
PMCPMC11380029

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.